Physiologie, Rolle und Neuropharmakologie des Gähnens

Zusammenfassung

Gähnen ist ein normales physiologisches Ereignis, das in drei unterschiedliche Phasen eingeteilt werden kann: eine lange inspiratorische Phase, einen kurzen Höhepunkt und eine schnelle Ausatemphase.

Der Grund für das Gähnen ist noch nicht klar definiert. Gähnen ist ein halb-freiwilliger Vorgang, der die Aufmerksamkeit erhöht und darauf abzielt, eine Weckreaktion hervorzurufen, wenn Schläfrigkeit auftritt. Eventuell spielt das Gähnen zusätzlich eine wichtige Rolle bei der sozialen Kommunikation. Die Neuropharmakologie des Gähnens ist sehr komplex und die Mechanismen sind noch wenig verstanden. Das Gähnen steht unter Kontrolle von verschiedenen Neurotransmittern, deren wichtigster Dopamin ist. Eine Modellvorstellung wäre, dass Dopamin die Oxytocin-Produktion im Nucleus paraventricularis des Hypothalamus aktivieren könnte und Oxytocin dann cholinerge Neurotransmission im Hippocampus auslöst. Acetylcholin könnte dann das Gähnen über muskarinerge Rezeptoren in den Effektororganen auslöst. Diese Modellvorstellung ist jedoch stark vereinfacht. Viele andere Moleküle können das Gähnen modulieren, wie z. B. NO, Glutamat, GABA, Serotonin, ACTH, MSH, Sexualhormone und Opioide.

Abstract

Yawning is a physiological event that can be divided into three distinct phases: a long inspiratory phase, a brief acme and a rapid exspiration. The reason for yawning is not yet well defined. However this semi-voluntary event increases vigilance and aims to alert when drowsiness occurs. Yawning may have an important role for social communication. The neuropharmacology of yawning is complex and knowledge of its mechanisms is incomplete. While under the control of several neurotransmitters, yawning is largely affected by dopamine. Dopamine may activate oxytocin production in the paraventricular nucleus of the hypothalamus, oxytocin may then activate cholinergic neurotransmission in the hippocampus, and finally acetylcholine might induce yawning via the muscarinic receptors of the effectors. In fact, this scheme is simplified. Many other molecules can modulate yawning, such as nitric oxide, glutamate, GABA, serotonine, ACTH, MSH, sexual hormones and opium derivate peptides.

Gähnen - Neuropharmakologie - Neurotransmitter - Schlaf

Yawning - Neuropharmacology - Neurotransmitters - Sleep

Literatur

• 1 Keil G. Hippokrates, gesammelte antike Schriften. In: Bautier RH (Hrsg) Lexikon des Mittelalters, 9 Bde und Registerband, Band 5. München/Zürich; 1991: 1980-1999
• 2 Chouard C H, Bigot-Massoni D. Mechanisms and physiologic role of yawning.  Ann Otolaryngol Chir Cervicofac. 1990;  107 145-153
• 3 Siegal S, Letter H. Why the yawn?.  N Engl J Med. 1974;  290 1027-1028
• 4 Lehmann H E. Yawning. A homeostatic reflex and its psychological significance.  Bull Menninger Clin. 1979;  43 123-126
• 5 Kavanau J L. Vertebrates that never sleep: implications for sleep’s basic function.  Brain Res Bull. 1998;  46 269-279
• 6 Walusinski O, Deputte B L. Yawn: from ethology to clinical medicine.  Rev Prat. 2002;  52 1981-1983
• 7 Code R A, Tang A H. Yawning produced by dopamine agonists in rhesus monkeys.  Eur J Pharmacol. 1991;  201 235-238
• 8 de Vries J I, Visser G H, Prechtl H F. The emergence of fetal behaviour. II. Quantitative aspects.  Early Hum Dev. 1985;  12 99-120
• 9 de Vries J I, Visser G H, Prechtl H F. Fetal behaviour in early pregnancy.  Eur J Obstet Gynecol Reprod Biol. 1986;  21 271-276
• 10 Lal S, Grassino A, Thavundayil J X. et al . A simple method for the study of yawning in man induced by the dopamine receptor agonist, apomorphine.  Prog Neuropsychopharmacol Biol Psychiatry. 1987;  11 223-228
• 11 Provine R R, Tate B C, Geldmacher L L. Yawning: no effect of 3 - 5 % CO₂, 100 % O₂, and exercise.  Behav Neural Biol. 1987;  48 382-393
• 12 Heusner P. Yawning and associated phenomena.  Physiol Rev. 1946;  26 156-168
• 13 Lal S, Tesfaye Y, Thavundayil J X. et al . Effect of time-of-day on the yawning response to apomorphine in normal subjects.  Neuropsychobiology. 2000;  41 178-180
• 14 Skorzewska A, Tesfaye Y, Krishnan B. et al . Effect of scopolamine on spontaneous yawning in men.  Neuropsychobiology. 1993;  27 17-20
• 15 Greco M, Baenninger R. Effects of yawning and related activities on skin conductance and heart rate.  Physiol Behav. 1991;  50 1067-1069
• 16 Garma H AL. Le baillement.  Psychiatry and Psychobiology. 1988;  3 275-286
• 17 Karasawa J, Kuriyama Y, Kuro M. et al . Monitoring system of cerebral blood flow and cerebral metabolism. Part II. Relationship between internal jugular O2 tention and cerebral blood flow (author’s transl.).  No To Shinkei. 1982;  34 239-245
• 18 Kuriyama Y, Sawada T, Niimi T. et al . Development of monitoring system of cerebral blood flow and cerebral metabolism. Part III. „In vitro module” of medical massspectrometer, and its clinical applications.  Kokyu To Junkan. 1983;  31 77-80
• 19 Sato-Suzuki I, Kita I, Oguri M. et al . Stereotyped yawning responses induced by electrical and chemical stimulation of paraventricular nucleus of the rat.  J Neurophysiol. 1998;  80 2765-2775
• 20 Baenninger R, Binkley S, Baenninger M. Field observations of yawning and activity in humans.  Physiol Behav. 1996;  59 421-425
• 21 Askenasy J J. Is yawning an arousal defense reflex?.  J Psychol. 1989;  123 609-621
• 22 Bell L. Boredom and the yawn. Review of the existential Psychology and Psychiatry.  Psychiatry and Psychobiology. 1980;  17 91-100
• 23 Charcot J. Lecon du mardi de la salpetriere.  Ann Otolaryngol Chir Cervicofac. 1990;  107 145-153
• 24 Blin O, Masson G, Azulay J P. et al . Apomorphine-induced blinking and yawning in healthy volunteers.  Br J Clin Pharmacol. 1990;  30 769-773
• 25 Blin O, Azulay J P, Masson G. et al . Yawning. Physiopathology and neuropharmacology.  Therapie. 1991;  46 37-43
• 26 Edvinsson L, McCulloch J, Sharkey J. Vasomotor responses of cerebral arterioles in situ to putative dopamine receptor agonists.  Br J Pharmacol. 1985;  85 403-410
• 27 Ferrari W, Gessa G L, Vargiu L. Behavioral effects induced by intracisternally injected ACTH and MSH.  Ann N Y Acad Sci. 1963;  104 330-345
• 28 Aubin L G. Le baillement.  Psychiatry and Psychobiology. 1988;  3 275-286
• 29 Gantz I, Shimoto Y, Konda Y. et al . Molecular cloning, expression, and characterization of a fifth melanocortin receptor.  Biochem Biophys Res Commun. 1994;  200 1214-1220
• 30 Fujikawa M, Yamada K, Nagashima M. et al . Involvement of beta-adrenoceptors in regulation of the yawning induced by neuropeptides, oxytocin and alpha-melanocyte-stimulating hormone, in rats.  Pharmacol Biochem Behav. 1995;  50 339-343
• 31 Gower A J, Berendsen H H, Broekkamp C L. Antagonism of drug-induced yawning and penile erections in rats.  Eur J Pharmacol. 1986;  122 239-244
• 32 Nickolson V J, Berendsen H H. Effects of the potential neuroleptic peptide des-tyrosine-gamma-endorphin and haloperidol on apomorphine-induced behavioural syndromes in rats and mice.  Life Sci. 1980;  27 1377-1385
• 33 Morelli M, Longoni R, Spina L. et al . Antagonism of apomorphine-induced yawning by SCH 23 390: evidence against the autoreceptor hypothesis.  Psychopharmacology (Berl). 1986;  89 259-260
• 34 Stahle L, Ungerstedt U. Yawning and suppression of exploration induced by dopamine agonists: no relation to extracellular striatal levels of dopamine.  Pharmacol Biochem Behav. 1990;  35 201-209
• 35 Stahle L, Ungerstedt U. Yawning and suppression of exploration in amphetamine-treated rats, incompatibility with the autoreceptor hypothesis.  Psychopharmacology (Berl). 1989;  97 553-560
• 36 Lynch M R. Dissociation of autoreceptor activation and behavioral consequences of low-dose apomorphine treatment.  Prog Neuropsychopharmacol Biol Psychiatry. 1991;  15 689-698
• 37 Buijs R M, Geffard M, Pool C W. et al . The dopaminergic innervation of the supraoptic and paraventricular nucleus. A light and electron microscopical study.  Brain Res. 1984;  323 65-72
• 38 Melis M R, Mauri A, Argiolas A. Apomorphine-and oxytocin-induced penile erection and yawning in intact and castrated male rats: effect of sexual steroids.  Neuroendocrinology. 1994;  59 349-354
• 39 Argiolas A, Melis M R, Gessa G L. Yawning: neurochemistry, physiology and pathology.  Cephalalgia. 1987;  7 Suppl 6 131-137
• 40 Argiolas A, Melis M R, Mauri A. et al . Oxytocin-induced penile erection and yawning in male rats: effect of neonatal monosodium glutamate and hypophysectomy.  Psychopharmacology (Berl). 1989;  97 383-387
• 41 Melis M R, Argiolas A, Stancampiano R. et al . Oxytocin-induced penile erection and yawning: structure-activity relationship studies.  Pharmacol Res Commun. 1988;  20 1117-1118
• 42 Argiolas A, Melis M R. The neuropharmacology of yawning.  Eur J Pharmacol. 1998;  343 1-16
• 43 Melis M R, Succu S, Argiolas A. Prevention by morphine of N-methyl-D-aspartic acid-induced penile erection and yawning: involvement of nitric oxide.  Brain Res Bull. 1997;  44 689-694
• 44 Melis M R, Succu S, Argiolas A. Dopamine agonists increase nitric oxide production in the paraventricular nucleus of the hypothalamus: correlation with penile erection and yawning.  Eur J Neurosci. 1996;  8 2056-2063
• 45 Schuman E M, Madison D V. Nitric oxide and synaptic function.  Annu Rev Neurosci. 1994;  17 153-183
• 46 Bredt D S, Hwang P M, Snyder S H. Localization of nitric oxide synthase indicating a neural role for nitric oxide.  Nature. 1990;  347 768-770
• 47 Protais P, Windsor M, Mocaer E. et al . Post-synaptic 5-HT1A receptor involvement in yawning and penile erections induced by apomorphine, physostigmine and mCPP in rats.  Psychopharmacology (Berl). 1995;  120 376-383
• 48 Wood D C, Costa E. Increase of the acetylcholin turnover rate and the stretching yawning syndrome elicited by MSH and ACTH.  Life Sciences. 1978;  22 673-675
• 49 Argiolas A, Melis M R, Murgia S. et al . ACTH- and alpha-MSH-induced grooming, stretching, yawning and penile erection in male rats: site of action in the brain and role of melanocortin receptors.  Brain Res Bull. 2000;  51 425-431
• 50 Sanchez M S, Celis M E, Schioth H B. Evidence that alpha-MSH induced grooming is not primarily mediated by any of the cloned melanocortin receptors.  Neuropeptides. 2000;  34 77-82
• 51 Davies J, Tongroach P. Neuropharmacological studies on the nigro-striatal and raphe-striatal system in the rat.  Eur J Pharmacol. 1978;  51 91-100
• 52 Matsumoto S, Yamada K, Nagashima M. et al . Potentiation by serotonergic inhibition of yawning induced by dopamine receptor agonists in rats.  Pharmacol Biochem Behav. 1989;  32 815-818
• 53 Zarrindast M R, Jamshidzadeh A. Inhibitory effect of morphine on yawning induced by cholinoceptor and dopamine D2 receptor activation in rats.  Br J Pharmacol. 1992;  105 675-678
• 54 Kimura H, Yamada K, Nagashima M. et al . Involvement of catecholamine receptor activities in modulating the incidence of yawning in rats.  Pharmacol Biochem Behav. 1996;  53 1017-1021
• 55 Melis M R, Argiolas A, Gessa G L. Apomorphine-induced penile erection and yawning: site of action in brain.  Brain Res. 1987;  415 98-104
• 56 Monaghan D T, Bridges R J, Cotman C W. The excitatory amino acid receptors: their classes, pharmacology, and distinct properties in the function of the central nervous system.  Annu Rev Pharmacol Toxicol. 1989;  29 365-402
• 57 Doger E, Urba-Holmgren R, Eguibar J R. et al . GABAergic modulation of yawning behavior.  Pharmacol Biochem Behav. 1989;  34 237-240
• 58 Yamada K, Emson P, Hokfelt T. Immunohistochemical mapping of nitric oxide synthase in the rat hypothalamus and colocalization with neuropeptides.  J Chem Neuroanat. 1996;  10 295-316